Agenus vs Replimune: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Agenus Inc (AGEN)

Q3 202613 Jul – 3 Oct 2026

▲3

Agenus funds its colon-cancer pivot, then posts ovarian survival data

Up to $340M private placement funds Phase 3 pivot Agenus raised about $85M upfront, potentially $340M if warrants are exercised, from investors led by Commodore Capital. The cash funds the ROBBIN Phase 3 colon-cancer trial and extends the runway, easing the biggest risk for a small biotech: running out of money.
This financing is the main force behind the period's huge share move and removes near-term funding risk.
Strategy narrowed to one lead colon-cancer trial Agenus dropped funding for its BATTMAN study and made ROBBIN its top priority: a global 850-patient Phase 3 testing botensilimab plus balstilimab before surgery in high-risk Stage II/III colon cancer, with first dosing expected early 2027.
The pipeline refocus explains why the money matters and what future value now hinges on.
Three-year ovarian cancer survival data reported In heavily pretreated recurrent ovarian cancer, the BOT+BAL combo showed 48% three-year overall survival, a 23% response rate and no new safety signals. Positive data supports the drug's broader potential, though it is early-stage and not the main colon-cancer bet.
This is the period's only new clinical result and adds evidence the drug platform works.
Stock's doubling reflects hope, not proven results Shares jumped roughly 80-100% on the financing, a huge move for a cash raise. That shows investors pricing in success, but the Phase 3 readout is years away and warrants could later dilute holders, so the rally rests on expectations rather than confirmed outcomes.
It gives the fair counterweight: the surge is sentiment-driven and still carries real execution and dilution risk.

August 202613 Jul – 3 Oct 2026

▲3

Agenus funds its colon-cancer pivot, then posts ovarian survival data

Up to $340M private placement funds Phase 3 pivot Agenus raised about $85M upfront, potentially $340M if warrants are exercised, from investors led by Commodore Capital. The cash funds the ROBBIN Phase 3 colon-cancer trial and extends the runway, easing the biggest risk for a small biotech: running out of money.
This financing is the main force behind the period's huge share move and removes near-term funding risk.
Strategy narrowed to one lead colon-cancer trial Agenus dropped funding for its BATTMAN study and made ROBBIN its top priority: a global 850-patient Phase 3 testing botensilimab plus balstilimab before surgery in high-risk Stage II/III colon cancer, with first dosing expected early 2027.
The pipeline refocus explains why the money matters and what future value now hinges on.
Three-year ovarian cancer survival data reported In heavily pretreated recurrent ovarian cancer, the BOT+BAL combo showed 48% three-year overall survival, a 23% response rate and no new safety signals. Positive data supports the drug's broader potential, though it is early-stage and not the main colon-cancer bet.
This is the period's only new clinical result and adds evidence the drug platform works.
Stock's doubling reflects hope, not proven results Shares jumped roughly 80-100% on the financing, a huge move for a cash raise. That shows investors pricing in success, but the Phase 3 readout is years away and warrants could later dilute holders, so the rally rests on expectations rather than confirmed outcomes.
It gives the fair counterweight: the surge is sentiment-driven and still carries real execution and dilution risk.

Latest13 Jul – 3 Oct 2026

▲3

Agenus funds its colon-cancer pivot, then posts ovarian survival data

Up to $340M private placement funds Phase 3 pivot Agenus raised about $85M upfront, potentially $340M if warrants are exercised, from investors led by Commodore Capital. The cash funds the ROBBIN Phase 3 colon-cancer trial and extends the runway, easing the biggest risk for a small biotech: running out of money.
This financing is the main force behind the period's huge share move and removes near-term funding risk.
Strategy narrowed to one lead colon-cancer trial Agenus dropped funding for its BATTMAN study and made ROBBIN its top priority: a global 850-patient Phase 3 testing botensilimab plus balstilimab before surgery in high-risk Stage II/III colon cancer, with first dosing expected early 2027.
The pipeline refocus explains why the money matters and what future value now hinges on.
Three-year ovarian cancer survival data reported In heavily pretreated recurrent ovarian cancer, the BOT+BAL combo showed 48% three-year overall survival, a 23% response rate and no new safety signals. Positive data supports the drug's broader potential, though it is early-stage and not the main colon-cancer bet.
This is the period's only new clinical result and adds evidence the drug platform works.
Stock's doubling reflects hope, not proven results Shares jumped roughly 80-100% on the financing, a huge move for a cash raise. That shows investors pricing in success, but the Phase 3 readout is years away and warrants could later dilute holders, so the rally rests on expectations rather than confirmed outcomes.
It gives the fair counterweight: the surge is sentiment-driven and still carries real execution and dilution risk.

Replimune Group Inc (REPL)

Q3 202623 Jun – 11 Aug 2026

▲2▼2

FDA panel backs RP1, approval and offering reshape Replimune

FDA panel backs RP1 An FDA advisory panel voted 10-3 that RP1's single-arm IGNYTE data were clinically meaningful, reversing earlier doubts and sending shares up over 130% premarket; Wedbush upgraded the stock.
This was the key regulatory catalyst that drove the stock's massive jump.
Accelerated approval of Tudriqev The FDA granted accelerated approval to Tudriqev plus Opdivo for advanced melanoma (24.2% response rate), giving Replimune its first commercial product and revenue stream.
This approval is a major milestone that transforms the company's business prospects.
Securities fraud investigations Two law firms (Kirby McInerney, Bragar Eagel & Squire) and later Pomerantz opened securities fraud investigations into whether the company misled investors before the FDA's critical July 28 briefing documents.
These investigations pose a legal overhang that could weigh on the stock.
Dilutive stock offering A $150 million stock offering at $12.06/share issued ~9.7 million new shares, diluting existing holders.
The offering dilutes current shareholders and can pressure the share price.

July 202623 Jun – 11 Aug 2026

▲2▼2

FDA panel backs RP1, approval and offering reshape Replimune

FDA panel backs RP1 An FDA advisory panel voted 10-3 that RP1's single-arm IGNYTE data were clinically meaningful, reversing earlier doubts and sending shares up over 130% premarket; Wedbush upgraded the stock.
This was the key regulatory catalyst that drove the stock's massive jump.
Accelerated approval of Tudriqev The FDA granted accelerated approval to Tudriqev plus Opdivo for advanced melanoma (24.2% response rate), giving Replimune its first commercial product and revenue stream.
This approval is a major milestone that transforms the company's business prospects.
Securities fraud investigations Two law firms (Kirby McInerney, Bragar Eagel & Squire) and later Pomerantz opened securities fraud investigations into whether the company misled investors before the FDA's critical July 28 briefing documents.
These investigations pose a legal overhang that could weigh on the stock.
Dilutive stock offering A $150 million stock offering at $12.06/share issued ~9.7 million new shares, diluting existing holders.
The offering dilutes current shareholders and can pressure the share price.

Latest23 Jun – 11 Aug 2026

▲2▼2

FDA approves Replimune's first drug, then company raises $150M

FDA grants accelerated approval for Tudriqev The FDA granted accelerated approval to Replimune's Tudriqev combined with Opdivo for advanced melanoma, based on a 24.2% response rate. This is the company's first commercial product, turning it from a clinical-stage hopeful into a revenue-generating business and lifting the stock.
This is the single biggest new event: approval validates the drug and opens a path to sales.
Securities fraud investigation expands to Pomerantz Pomerantz LLP opened an investigation into whether Replimune misled investors before the FDA's July 28 briefing documents questioned the RP1 data. This adds to earlier law firm probes, keeping a legal cloud over the stock and potentially weighing on the price.
It is a new law firm joining the investigation, adding fresh negative pressure.
$150 million stock offering dilutes shareholders Replimune priced a $150 million stock sale at $12.06 per share, issuing about 9.7 million new shares. This raises cash to launch Tudriqev but dilutes existing investors' ownership, which typically pushes the stock down in the short term.
It is a new financing event that directly affects share count and cash position.
FDA flexibility and biotech rally support Replimune The FDA signaled a more flexible approval approach for serious diseases, opening new pathways for Replimune and others. This supportive regulatory backdrop helped biotech stocks broadly and made RP1's eventual approval more likely, lifting sentiment around Replimune.
It explains the favorable regulatory environment that helped Replimune's path to approval.

30 Jul – 31 Jul 2026

▲2▼1

FDA panel backs RP1, reversing prior briefing-document collapse

FDA advisory panel votes 10-3 in favor of RP1 An FDA advisory committee voted 10 to 3 that RP1's single-arm IGNYTE study results are evaluable and clinically meaningful for advanced melanoma. This removes the main regulatory doubt and makes approval by the August 2 target date far more likely, pushing the stock sharply higher.
This is the core new event that flipped sentiment and drove the huge price jump.
Stock surges over 130% premarket, analyst upgrade Replimune shares soared more than 130% before the open and were up about 94-125% during the day after the panel vote. Wedbush upgraded the stock to outperform from neutral, a sign that professional investors now see the approval path as much clearer.
Shows the market's immediate, large positive reaction and a key analyst endorsement.
Securities fraud investigations launched Two law firms, Kirby McInerney and Bragar Eagel & Squire, opened investigations into whether Replimune misled investors before the FDA's July 28 briefing documents called the RP1 study non-interpretable. No lawsuit has been filed yet, but this legal cloud could weigh on the stock.
A real counterweight that could hurt the stock even after the positive panel vote.